Editorial: Pathophysiology and pharmacological treatments associated with liver failures.
| Autor: | Herath CB; Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Australia., El Hiba O; Laboratory of Anthropogenic, Biotechnology and Health, Nutritional Physiopathologies, Neurosciences and Toxicology Team, Faculty of Sciences, Chouaib Doukkali University, El Jadida, Morocco., Zhou X; Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, China., Luo X; Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China., Lu K; Division of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, Heinrich Heine University of Düsseldorf, Düsseldorf, Germany. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in pharmacology [Front Pharmacol] 2024 Apr 12; Vol. 15, pp. 1407835. Date of Electronic Publication: 2024 Apr 12 (Print Publication: 2024). |
| DOI: | 10.3389/fphar.2024.1407835 |
| Abstrakt: | Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|